Susmed (TSE:4263) ROCE %: -33.42% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4263 Susmed Inc TSE:4263
60 GF Score
Price 円576.00
GF Value 円904.97
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Susmed ROCE %?

Susmed TSE:4263 +0.52% 60 ROCE % is -33.42% as of Mar. 2026. GuruFocus rates TSE:4263 with a GF Score™ of 60/100 and a GF Value™ of 円904.97 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Susmed's annualized ROCE % for the quarter that ended in Mar. 2026 was -33.42%.

Susmed  (TSE:4263) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Susmed ROCE % Related Terms

Susmed ROCE % Historical Data

* Premium members only.

The historical data trend for Susmed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Susmed ROCE % Chart

Susmed Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
ROCE %
Get a 7-Day Free Trial -7.12 -0.99 -7.69 -6.66 -7.82

Susmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.68 -12.33 -14.56 -33.42 29.45
TSE:4263
60GF Score
Susmed Inc TSE:4263
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Susmed ROCE % Calculation

Susmed's annualized ROCE % for the fiscal year that ended in Jun. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2026 )  (A: Jun. 2025 )(A: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2026 )  (A: Jun. 2025 )(A: Jun. 2026 )
=-330.16/( ( (4502.972 - 125.94) + (4218.107 - 147.943) )/ 2 )
=-330.16/( (4377.032+4070.164)/ 2 )
=-330.16/4223.598
=-7.82 %

Susmed's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-1380.508/( ( (4271.094 - 117.263) + (4223.251 - 114.372) )/ 2 )
=-1380.508/( ( 4153.831 + 4108.879 )/ 2 )
=-1380.508/4131.355
=-33.42 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -33.42% mean?
Susmed (TSE:4263) has a ROCE % of -33.42% as of Mar. 2026.
Is Susmed's ROCE % too high?
Susmed's current ROCE % is -33.42%. Overall, Susmed has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Susmed's ROCE % compare to VEEV and BTSG?
Susmed's ROCE % of -33.42% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.59, based on 643 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Susmed's current ROCE % is -33.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Possible Value Trap. The stock's GF Value™ is 円904.97, compared to a current price of 円576.00 — trading 36.4% below its estimated fair value. The current ROCE % is -33.42%. Susmed's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Susmed (TSE:4263), the current ROCE % is -33.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円576.00 is trading 36.4% below its estimated GF Value™ of 円904.97. GuruFocus considers Susmed to be Possible Value Trap.

Key valuation signals for TSE:4263:

  • ROCE %: -33.42%
  • GF Value™: 円904.97 vs. price of 円576.00 (36.4% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
60GF Score

Get the complete analysis for TSE:4263

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円576.00
Price
円904.97
GF Value